There is one critical aspect to the stock market that pertains to American International Group (NYSE: AIG) which has been given less coverage because of the media’s focus on the turmoil in…
Investors have another reason to bail out of Boston Scientific (BSX). It has been in a battle with the medical research community for over a year fighting the perception that its drug-coated…
We saw another exciting week full of news for key developments in drug stocks, biotech stocks, medical device stocks, and other companies involved in various aspects of health care and medicine. Below…
According to Reuters, US stock indices entered a bear market phase. Reuters writes that Yahoo! (YHOO) and Microsoft (MSFT) are exploring media tie-ups with other internet companies.. Reuters reports that The Weather…
With the trading year almost half over and results from the first quarter out, 24/7 Wall St. has created the latest installment of its Ten Worst Managed Companies In America list. This…
Boston Scientific (BSX) has been the "gang who couldn’t shot straight" of the medical device business for some time. It spent far too much money to buy another medical company, Guidant. For…
These are ten of the impact analyst calls we are seeing this Friday morning: Abbott Labs (NYSE: ABT) started as Buy at UBS. Advanced Energy (NASDAQ: AEIS) Raised To Overweight By JP…
Thursday after the close, we’ll get to see earnings out of Genentech (NASDAQ: DNA). The estimates from First Call are $0.82 EPS on $3.11 billion in revenues. Next quarter estimates are $0.86…
These are the top analyst calls we are focusing on early this Thursday morning in pre-market trading: Abbott Laboratories (NYSE: ABT) Raised To Outperform at Wachovia. Altria (NYSE: MO) started as Buy…
Medtronic, Inc. (NYSE: MDT) has just announced that it has received formal approval from the FDA to market its Endeavor Zotarolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. This…
We are full fledged into earnings season now, so most news coverage will point to the current earnings environment and guidance. There are of course drug developments and other contracts awards. Below…
James Tobin, the CEO of Boston Scientific (NYSE:BSX) is likely to find himself in front of the shareholder firing squad in 2008. In early 2004 this stock was above $40 and had…
Abbott Labs (ABT) which just launched a new stent product, Xience V, has laid off 1,200 people because of slowness in the stent market. Stranger than fiction. According to MarketWatch, Abbott says…
According to Reuters, Fed chief Bernanke said the resurgence in financial strains in recent weeks had dimmed the outlook for the U.S. economy. Reuters writes that Dell’s (DELL) profit rose but if…
Abbot Labs (ABT) is trying to get into the stent business. The market has been dominated by Boston Scientific (BSX) and Johnson & Johnson (JNJ). Stents are small mess implants which are…
